Welcome to our dedicated page for Integer Hldgs news (Ticker: ITGR), a resource for investors and traders seeking the latest updates and insights on Integer Hldgs stock.
Integer Holdings Corporation (NYSE: ITGR) is a medical device contract development and manufacturing organization (CDMO) that regularly issues news on its operations, financial performance, and corporate developments. The company focuses on serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets, and its updates reflect activity across these areas.
On this page, readers can follow ITGR news related to quarterly earnings, product line performance, and outlooks that Integer provides through press releases furnished with Form 8-K filings. These releases often include discussions of sales trends in Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and Other Markets, along with non-GAAP financial measures such as adjusted operating income, adjusted EBITDA, adjusted net income, and adjusted earnings per share.
Integer’s news flow also covers strategic and governance events, such as leadership transitions, board appointments, and capital allocation decisions. Recent examples include the appointment of a new President and Chief Executive Officer, the election of a new director with extensive medical device industry experience, and the authorization of a share repurchase program by the Board of Directors.
In addition, Integer publishes updates on technology and market-facing activities, such as participation in medical society meetings and healthcare investor conferences. The company has highlighted innovations in neuromodulation and miniaturized active implantable medical devices, including high-performance batteries and integrated implantable pulse generator and lead systems, as well as its Xcellion Gen 3 fast charge lithium ion battery technology.
Investors and observers can use this news page to monitor how Integer communicates its strategy, product line dynamics, financing actions, and role as a CDMO in the cardiac rhythm management, neuromodulation, and cardio and vascular markets.
Integer Holdings Corporation (NYSE:ITGR) reported a 12% increase in sales for Q2 2022, totaling $350 million, aided by recent acquisitions. However, GAAP net income decreased by 29% to $21 million, and GAAP diluted EPS dropped to $0.62, down $0.27 per share. The company raised its full-year sales outlook to 12%-14% growth, driven by demand in electrophysiology and structural heart markets. However, total debt rose to $947 million, increasing the leverage ratio to 3.9 times adjusted EBITDA.
Integer Holdings Corporation (NYSE:ITGR) plans to release its financial and operational results for Q2 2022 on July 28, 2022, at 7 a.m. CT / 8 a.m. ET. Following the release, management will host a webcast at 8 a.m. CT / 9 a.m. ET to discuss the results and any other forward-looking information. Key details include domestic and international dial-in numbers and the registration link for the webcast.
Integer Holdings Corporation (NYSE:ITGR) reported a 7% increase in sales to $311 million for Q1 2022, despite facing challenges from COVID-19 absenteeism and supply chain constraints. GAAP net income fell by 47% to $11 million. The company completed the acquisition of Aran Biomedical, enhancing its product offerings in the cardiovascular market, expected to add $90 million in annual sales. For 2022, Integer anticipates 11% to 13% sales growth with continued efforts to improve gross margins and address labor challenges.
Integer Holdings Corporation (NYSE: ITGR) announced the acquisition of Connemara Biomedical Holdings for €120 million, with an additional €10 million contingent on 2022 revenue growth. This acquisition enhances Integer's capabilities in implantable medical devices, particularly in the cardiovascular sector, where Aran Biomedical's expertise in biomaterials will complement Integer's existing offerings. Aran Biomedical generated $17 million in sales in 2021, nearly doubling from the previous year, and the acquisition is immediately accretive to Integer’s sales growth and profit margins.
Integer Holdings Corporation (NYSE:ITGR) will announce its first quarter 2022 financial results on April 28, 2022, at 7 a.m. CT. A conference call will follow at 8 a.m. CT, featuring management's discussion on the results and potential forward-looking insights. Investors can join the call domestically at (888) 330-3567 or internationally at (646) 960-0842, using Conference ID 9252310. The event will also be available via webcast. Integer is a leading medical device manufacturer, serving various markets and providing high-quality technologies.
Integer Holdings Corporation (NYSE:ITGR) announced that CEO Joe Dziedzic and CFO Jason Garland will participate in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum. This event is scheduled for March 23, 2022, at 3:45 PM ET. A live webcast will be available on the company's website, with a replay offered post-event. Integer is a leading medical device outsource manufacturer, serving various markets including cardiac and orthopedics, and develops specialized batteries for niche applications.
Integer Holdings Corporation (NYSE:ITGR) announced the retirement of Bill R. Sanford as Chair of the Board, effective after the 2022 annual meeting on May 18, 2022. Pamela G. Bailey, a long-standing board member since 2002, will succeed him. Sanford has served 14 years as Chair and contributed to the company’s strategic growth. Bailey's extensive experience, including her tenure as President and CEO of AdvaMed, is expected to ensure a seamless leadership transition. Integer is a leading medical device outsource manufacturer serving various markets.
Graham Corporation (NYSE: GHM) announced the appointment of Christopher J. Thome as Vice President - Finance and Chief Financial Officer, effective April 4, 2022. Thome joins from Allied Motion Technologies (NASDAQ: AMOT) with nearly 30 years of finance experience. CEO Daniel J. Thoren expressed optimism about Thome's expertise in financial controls and operational knowledge, which could enhance the company's growth potential in defense and energy sectors. Thome succeeds Jeffrey F. Glajch, who retired.
Integer Holdings Corporation (NYSE: ITGR) reported a strong financial performance for Q4 and FY 2021, highlighting a 16% increase in Q4 sales to $313 million and a 14% increase in full-year sales to $1.221 billion. GAAP income from continuing operations rose by 30% in Q4, reaching $20 million, while full-year GAAP income climbed by 20% to $93 million. The company completed the acquisition of Oscor Inc. in December 2021, contributing to a total debt increase of $197 million to $828 million. Looking ahead, Integer projects sales growth of 10% to 12% for 2022.
Integer Holdings Corporation (NYSE:ITGR) will announce its financial results for Q4 and full year 2021 on February 17, 2022, at 7 a.m. CT. A webcast will follow at 8 a.m. CT to discuss these results and potential forward-looking information. Investors can access the call via domestic and international dial-in numbers or register for the webcast through the provided link. Integer specializes in medical device outsourcing and develops innovative technologies across various healthcare sectors.